Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on August 16, 2018. The filing reports the entry into a Material Definitive Agreement with Merck Sharp & Dohme B.V. (Merck) to conduct a Phase 2 clinical trial evaluating the combination of Rexahn's RX-5902 and Merck's KEYTRUDA (pembrolizumab) for metastatic triple negative breast cancer (TNBC).
Key Financial Metrics
This filing does not contain historical financial statements, revenue, profit, cash flow, or debt metrics. The only financial figure disclosed is the estimated cost for Rexahn to conduct the clinical trial, which is approximately $8.5 million.
Material Changes
- Collaboration Agreement: Rexahn entered into a collaboration with Merck where Merck will supply KEYTRUDA at no cost for the trial.
- Data Ownership: Clinical data generated from the trial will be jointly owned by Rexahn and Merck.
- Trial Timeline: The first patient is anticipated to be enrolled in early 2019, with the trial expected to last approximately two years.
Outlook, Risks, and Management Commentary
Management anticipates the trial will take approximately two years. The agreement includes termination clauses for material breach, safety concerns, regulatory actions, or discontinuation of development by either party. The filing includes a Safe Harbor statement noting that forward-looking statements regarding clinical development timelines, costs, and biological mechanisms are subject to uncertainties and risks that could cause actual results to differ materially.
Investor Verification Checklist
- Verify the full text of the Collaboration Agreement in the upcoming Form 10-Q for the quarter ending September 30, 2018.
- Monitor the actual enrollment date of the first patient against the "early 2019" estimate.
- Track the actual costs incurred for the trial against the $8.5 million estimate.
- Review subsequent filings for any updates on the safety or efficacy data from the Phase 2 trial.